Paracetamol interactions
Checked as Acetaminophen in this data source.
Full monograph for ParacetamolCheck it against another medicine
Medicines
664 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Ethanol + Isopropyl alcohol | Major | Metabolism | Chronic, excessive consumption of alcohol may increase the risk of acetaminophen-induced hepatotoxicity, which has included rare cases of fatal hepatitis and… | 12 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Lidocaine + Prilocaine | Major | Synergy | Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite. Coadministration with other oxidizing agents that can also induce… | 6 sources — open the full entry |
| Activated Charcoal | Moderate | Absorption | Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects… | 25 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Benzocaine + Butamben + Tetracaine Hydrochloride | Moderate | Synergy | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other… | 7 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Limited data suggest that carbamazepine may increase the potential hepatotoxicity of acetaminophen and decrease its pharmacologic effects. The mechanism may be… | 6 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with ceritinib may increase the plasma concentration and the risk of adverse effects of drugs that are substrates of CYP450 2A6 and/or 2E1… | 8 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Synergy · Unknown | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other…3 documented mechanisms | 7 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Synergy · Unknown | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other…3 documented mechanisms | 7 sources — open the full entry |
| Dapsone | Moderate | Synergy | Coadministration of oral or topical dapsone with other agents associated with methemoglobinemia may have additive effects and theoretically increase the risk… | 2 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with deferasirox may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 isoenzyme. The mechanism is decreased… | 2 sources — open the full entry |
| Efavirenz | Moderate | Synergy | Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with… | 7 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes… | 4 sources — open the full entry |
| Fenofibrate | Moderate | Metabolism | Coadministration with fenofibrate may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of CYP450 2C19, 2A6, and 2C9… | 37 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Metabolism | Hydantoins may increase the potential hepatotoxicity of acetaminophen and decrease its pharmacologic effects. The mechanism may be related to induction of… | 22 sources — open the full entry |
| Hydroxyprogesterone Caproate | Moderate | Metabolism | Coadministration with hydroxyprogesterone may decrease the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2A6, and/or 2B6. | 1 sources — open the full entry |
| Imatinib Mesylate | Moderate | Synergy | In vitro inhibition data suggest that coadministration with imatinib may increase the plasma concentrations of acetaminophen. The proposed mechanism is… | 5 sources — open the full entry |
| L-Asparginase | Moderate | Synergy | Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal… | 13 sources — open the full entry |
| Lidocaine Hydrochloride (Jelly) | Moderate | Synergy | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other… | 7 sources — open the full entry |
| Lorlatinib | Moderate | Metabolism | Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the uridine diphosphate glucuronosyl transferase (UGT)… | 5 sources — open the full entry |
| Methotrexate | Moderate | Synergy | Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher… | 3 sources — open the full entry |
| Ospemifene | Moderate | Excretion | Ospemifene and its major metabolite, 4-hydroxyospemifene, may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates… | 3 sources — open the full entry |
| Oxybuprocaine Hydrochloride | Moderate | Synergy | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other… | 7 sources — open the full entry |
| Phenobarbital | Moderate | Metabolism | Barbiturates may increase the hepatotoxic potential of acetaminophen and decrease its therapeutic effects. The mechanism may be related to accelerated CYP450… | 4 sources — open the full entry |
| Phenytoin Sodium | Moderate | Metabolism | Hydantoins may increase the potential hepatotoxicity of acetaminophen and decrease its pharmacologic effects. The mechanism may be related to induction of… | 22 sources — open the full entry |
| Primidone | Moderate | Metabolism | Barbiturates may increase the hepatotoxic potential of acetaminophen and decrease its therapeutic effects. The mechanism may be related to accelerated CYP450… | 4 sources — open the full entry |
| Proparacaine Hydrochloride | Moderate | Synergy | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other… | 7 sources — open the full entry |
| Remdesivir | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Rifampicin + Isoniazid | Moderate | Metabolism · Synergy | Some reports have suggested that isoniazid may increase the potential hepatotoxicity of acetaminophen. The mechanism may be related to induction of CYP450 2E1…2 documented mechanisms | 14 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Moderate | Metabolism · Synergy · Unknown | Some reports have suggested that isoniazid may increase the potential hepatotoxicity of acetaminophen. The mechanism may be related to induction of CYP450 2E1…4 documented mechanisms | 14 sources — open the full entry |
| Tea tree oil + Echinacea + Geothermal water | Moderate | Metabolism | Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed… | 1 sources — open the full entry |
| Thiopental Sodium | Moderate | Metabolism | Barbiturates may increase the hepatotoxic potential of acetaminophen and decrease its therapeutic effects. The mechanism may be related to accelerated CYP450… | 4 sources — open the full entry |
| Warfarin Sodium | Moderate | Synergy | Acetaminophen (APAP) may potentiate the hypoprothrombinemic effect of warfarin and other vitamin K antagonists, although data are somewhat conflicting and the… | 48 sources — open the full entry |
| Atropine Sulfate (Injection) | Minor | Absorption | Anticholinergic agents may delay and/or decrease the gastrointestinal absorption of acetaminophen by reducing gastric motility and delaying gastric emptying… | 6 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Minor | Absorption · Unknown | Anticholinergic agents may delay and/or decrease the gastrointestinal absorption of acetaminophen by reducing gastric motility and delaying gastric emptying…2 documented mechanisms | 6 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Minor | Others | Animal studies have suggested that pretreatment with sodium salicylate may decrease the potential hepatotoxicity of acetaminophen. | 1 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Minor | Others | Animal studies have suggested that pretreatment with sodium salicylate may decrease the potential hepatotoxicity of acetaminophen. | 1 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Minor | Absorption · Unknown | Anticholinergic agents may delay and/or decrease the gastrointestinal absorption of acetaminophen by reducing gastric motility and delaying gastric emptying…3 documented mechanisms | 6 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Minor | Others · Unknown | Animal studies have suggested that pretreatment with sodium salicylate may decrease the potential hepatotoxicity of acetaminophen.2 documented mechanisms | 1 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Minor | Others | Animal studies have suggested that pretreatment with sodium salicylate may decrease the potential hepatotoxicity of acetaminophen. | 1 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Minor | Antagonism | Oral contraceptives may decrease or delay the effects of acetaminophen by increasing glucuronidation. With the usual therapeutic dosage, concurrent… | 37 sources — open the full entry |
| Darifenacin | Minor | Absorption | Anticholinergic agents may delay and/or decrease the gastrointestinal absorption of acetaminophen by reducing gastric motility and delaying gastric emptying… | 6 sources — open the full entry |
| Dicycloverine Hydrochloride | Minor | Absorption | Anticholinergic agents may delay and/or decrease the gastrointestinal absorption of acetaminophen by reducing gastric motility and delaying gastric emptying… | 6 sources — open the full entry |
| Dithranol + Boric Acid + Salicylic Acid | Minor | Others | Animal studies have suggested that pretreatment with sodium salicylate may decrease the potential hepatotoxicity of acetaminophen. | 1 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Minor | Antagonism | Oral contraceptives may decrease or delay the effects of acetaminophen by increasing glucuronidation. With the usual therapeutic dosage, concurrent… | 37 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Minor | Antagonism | Oral contraceptives may decrease or delay the effects of acetaminophen by increasing glucuronidation. With the usual therapeutic dosage, concurrent… | 37 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Minor | Antagonism | Oral contraceptives may decrease or delay the effects of acetaminophen by increasing glucuronidation. With the usual therapeutic dosage, concurrent… | 37 sources — open the full entry |
| Ethinyl Estradiol + Gestodene | Minor | Antagonism | Oral contraceptives may decrease or delay the effects of acetaminophen by increasing glucuronidation. With the usual therapeutic dosage, concurrent… | 37 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Minor | Antagonism · Unknown | Oral contraceptives may decrease or delay the effects of acetaminophen by increasing glucuronidation. With the usual therapeutic dosage, concurrent…2 documented mechanisms | 37 sources — open the full entry |
Food & lifestyle
alcohol
MajorMetabolism
Chronic, excessive consumption of alcohol may increase the risk of acetaminophen-induced hepatotoxicity, which has included rare cases of fatal hepatitis and frank hepatic failure requiring liver transplantation. The proposed mechanism is induction of hepatic microsomal enzymes during chronic alcohol use, which may result in accelerated metabolism of acetaminophen and increased production of potentially hepatotoxic metabolites.
What to do: In general, chronic alcoholics should avoid regular or excessive use of acetaminophen. Alternative analgesic/antipyretic therapy may be appropriate in patients who consume three or more alcoholic drinks per day. However, if acetaminophen is used, these patients should be cautioned not to exceed the recommended dosage (maximum 4 g/day in adults and children 12 years of age or older).
12 sources
- Kaysen GA, Pond SM, Roper MH, Menke DJ, Marrama MA "Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen." Arch Intern Med 145 (1985): 2019-23
- O'Dell JR, Zetterman RK, Burnett DA "Centrilobular hepatic fibrosis following acetaminophen-induced hepatic necrosis in an alcoholic." JAMA 255 (1986): 2636-7
- Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB "Acetaminophen hepatotoxicity in alcoholics." Ann Intern Med 104 (1986): 399-404
- Thummel KE, Slattery JT, Nelson SD "Mechanism by which ethanol diminishes the hepatotoxicity of acetaminophen." J Pharmacol Exp Ther 245 (1988): 129-36
- McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL "Potentiation of acetaminophen hepatotoxicity by alcohol." JAMA 244 (1980): 251-3
- Kartsonis A, Reddy KR, Schiff ER "Alcohol, acetaminophen, and hepatic necrosis." Ann Intern Med 105 (1986): 138-9
- Prescott LF, Critchley JA "Drug interactions affecting analgesic toxicity." Am J Med 75 (1983): 113-6
- "Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical (2002):
Show all 12 sourcesShow fewer sources
- Whitcomb DC, Block GD "Association of acetaminopphen hepatotoxicity with fasting and ethanol use." JAMA 272 (1994): 1845-50
- Bonkovsky HL "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995): 301
- Nelson EB, Temple AR "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995): 301
- Zimmerman HJ, Maddrey WC "Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure." Hepatology 22 (1995): 767-73
Conditions
Conditions in which Paracetamol needs care, as documented in this source.
Alcoholism
MajorChronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.
11 sources
- Kaysen GA, Pond SM, Roper MH, Menke DJ, Marrama MA "Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen." Arch Intern Med 145 (1985): 2019-23
- O'Dell JR, Zetterman RK, Burnett DA "Centrilobular hepatic fibrosis following acetaminophen-induced hepatic necrosis in an alcoholic." JAMA 255 (1986): 2636-7
- Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB "Acetaminophen hepatotoxicity in alcoholics." Ann Intern Med 104 (1986): 399-404
- McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL "Potentiation of acetaminophen hepatotoxicity by alcohol." JAMA 244 (1980): 251-3
- Kartsonis A, Reddy KR, Schiff ER "Alcohol, acetaminophen, and hepatic necrosis." Ann Intern Med 105 (1986): 138-9
- Prescott LF, Critchley JA "Drug interactions affecting analgesic toxicity." Am J Med 75 (1983): 113-6
- "Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical (2002):
- Whitcomb DC, Block GD "Association of acetaminopphen hepatotoxicity with fasting and ethanol use." JAMA 272 (1994): 1845-50
Show all 11 sourcesShow fewer sources
- Bonkovsky HL "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995): 301
- Nelson EB, Temple AR "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995): 301
- Zimmerman HJ, Maddrey WC "Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure." Hepatology 22 (1995): 767-73
Liver Diseases
MajorAcetaminophen is primarily metabolized in the liver to inactive forms. However, small quantities are converted by minor pathways to metabolites that can cause hepatotoxicity or methemoglobinemia. Patients with hepatic impairment may be at increased risk of toxicity due to increased minor metabolic pathway activity. Likewise, chronic or overuse of acetaminophen can saturate the primary hepatic enzymes and lead to increased metabolism by minor pathways. Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously in patients with hepatic insufficiency. Clinical monitoring of hepatic function is recommended. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.
6 sources
- Gillette JR "An integrated approach to the study of chemically reactive metabolites of acetaminophen." Arch Intern Med 141 (1981): 375-9
- Arnman R, Olsson R "Elimination of paracetamol in chronic liver disease." Acta Hepatogastroenterol (Stuttg) 25 (1978): 283-6
- Clements JA, Critchley JA, Prescott LF "The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man." Br J Clin Pharmacol 18 (1984): 481-5
- Forrest JA, Adriaenssens P, Finlayson ND, Prescott LF "Paracetamol metabolism in chronic liver disease." Eur J Clin Pharmacol 15 (1979): 427-31
- Venkataramanan R, Kalp K, Rabinovitch M, et al. "Conjugative drug metabolism in liver transplant patients." Transplant Proc 21 (1989): 2455
- "Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical (2002):
Phenylketonurias
ModerateSeveral oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).
1 source
- "Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical (2002):